Selected research
Industry Research
Cone-rod Dystrophy Treatment Industry Research Report 2026
Market perspective
Global Cone-rod Dystrophy Treatment includes JCyte, Nanoscope Therapeutics, SparingVision, MeiraGTx, AGTC, Biogen, etc. North America is the largest market, with a share about 60%, followed by Europe and Asia-Pacific.
Report Scope
This report quantifies the global Cone-rod Dystrophy Treatment market in terms of revenue (US$ million) and, where applicable, service volume (), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
Read the full market overview
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Cone-rod Dystrophy Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cone-rod Dystrophy Treatment Market by Company
JCyte
Nanoscope Therapeutics
SparingVision
MeiraGTx
AGTC
Biogen
Second Sight Medical
GlaxoSmithKline
Johnson And Johnson
Sanofi
Pfizer
Novartis
Abbott Laboratories
Cone-rod Dystrophy Treatment Segment by Type
Gene Therapy
Stem Cell Therapy
Retinal Implant Surgery
Cone-rod Dystrophy Treatment Segment by Application
Hospital
Ophthalmology Department
Other
Cone-rod Dystrophy Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cone-rod Dystrophy Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cone-rod Dystrophy Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cone-rod Dystrophy Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Cone-rod Dystrophy Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Gene Therapy
- Stem Cell Therapy
- Retinal Implant Surgery
Applications
- Hospital
- Ophthalmology Department
- Other
Companies covered
- JCyte
- Nanoscope Therapeutics
- SparingVision
- MeiraGTx
- AGTC
- Biogen
- Second Sight Medical
- GlaxoSmithKline
- Johnson And Johnson
- Sanofi
- Pfizer
- Novartis
- Abbott Laboratories
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cone-rod Dystrophy Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Gene Therapy
- 2.2.3 Stem Cell Therapy
- 2.2.4 Retinal Implant Surgery
- 2.3 Cone-rod Dystrophy Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Ophthalmology Department
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Cone-rod Dystrophy Treatment Breakdown Data by Type
- 3.1 Global Cone-rod Dystrophy Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Cone-rod Dystrophy Treatment Forecasted Market Size by Type (2027-2032)
4 Cone-rod Dystrophy Treatment Breakdown Data by Application
- 4.1 Global Cone-rod Dystrophy Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Cone-rod Dystrophy Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Cone-rod Dystrophy Treatment Market Perspective (2021-2032)
- 5.2 Global Cone-rod Dystrophy Treatment Growth Trends by Region
- 5.2.1 Global Cone-rod Dystrophy Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Cone-rod Dystrophy Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Cone-rod Dystrophy Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Cone-rod Dystrophy Treatment Market Dynamics
- 5.3.1 Cone-rod Dystrophy Treatment Industry Trends
- 5.3.2 Cone-rod Dystrophy Treatment Market Drivers
- 5.3.3 Cone-rod Dystrophy Treatment Market Challenges
- 5.3.4 Cone-rod Dystrophy Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Cone-rod Dystrophy Treatment Players by Revenue
- 6.1.1 Global Top Cone-rod Dystrophy Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Cone-rod Dystrophy Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Cone-rod Dystrophy Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Cone-rod Dystrophy Treatment Head Office and Area Served
- 6.4 Global Cone-rod Dystrophy Treatment Players, Product Type & Application
- 6.5 Global Cone-rod Dystrophy Treatment Manufacturers Established Date
- 6.6 Global Cone-rod Dystrophy Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Cone-rod Dystrophy Treatment Market Size (2021-2032)
- 7.2 North America Cone-rod Dystrophy Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Cone-rod Dystrophy Treatment Market Size by Country (2021-2026)
- 7.4 North America Cone-rod Dystrophy Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Cone-rod Dystrophy Treatment Market Size (2021-2032)
- 8.2 Europe Cone-rod Dystrophy Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Cone-rod Dystrophy Treatment Market Size by Country (2021-2026)
- 8.4 Europe Cone-rod Dystrophy Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Cone-rod Dystrophy Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Cone-rod Dystrophy Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Cone-rod Dystrophy Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Cone-rod Dystrophy Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Cone-rod Dystrophy Treatment Market Size (2021-2032)
- 10.2 South America Cone-rod Dystrophy Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Cone-rod Dystrophy Treatment Market Size by Country (2021-2026)
- 10.4 South America Cone-rod Dystrophy Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Cone-rod Dystrophy Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Cone-rod Dystrophy Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Cone-rod Dystrophy Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Cone-rod Dystrophy Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 JCyte
- 12.1.1 JCyte Company Information
- 12.1.2 JCyte Business Overview
- 12.1.3 JCyte Revenue in Cone-rod Dystrophy Treatment Business (2021-2026)
- 12.1.4 JCyte Cone-rod Dystrophy Treatment Product Portfolio
- 12.1.5 JCyte Recent Developments
- 12.2 Nanoscope Therapeutics
- 12.2.1 Nanoscope Therapeutics Company Information
- 12.2.2 Nanoscope Therapeutics Business Overview
- 12.2.3 Nanoscope Therapeutics Revenue in Cone-rod Dystrophy Treatment Business (2021-2026)
- 12.2.4 Nanoscope Therapeutics Cone-rod Dystrophy Treatment Product Portfolio
- 12.2.5 Nanoscope Therapeutics Recent Developments
- 12.3 SparingVision
- 12.3.1 SparingVision Company Information
- 12.3.2 SparingVision Business Overview
- 12.3.3 SparingVision Revenue in Cone-rod Dystrophy Treatment Business (2021-2026)
- 12.3.4 SparingVision Cone-rod Dystrophy Treatment Product Portfolio
- 12.3.5 SparingVision Recent Developments
- 12.4 MeiraGTx
- 12.4.1 MeiraGTx Company Information
- 12.4.2 MeiraGTx Business Overview
- 12.4.3 MeiraGTx Revenue in Cone-rod Dystrophy Treatment Business (2021-2026)
- 12.4.4 MeiraGTx Cone-rod Dystrophy Treatment Product Portfolio
- 12.4.5 MeiraGTx Recent Developments
- 12.5 AGTC
- 12.5.1 AGTC Company Information
- 12.5.2 AGTC Business Overview
- 12.5.3 AGTC Revenue in Cone-rod Dystrophy Treatment Business (2021-2026)
- 12.5.4 AGTC Cone-rod Dystrophy Treatment Product Portfolio
- 12.5.5 AGTC Recent Developments
- 12.6 Biogen
- 12.6.1 Biogen Company Information
- 12.6.2 Biogen Business Overview
- 12.6.3 Biogen Revenue in Cone-rod Dystrophy Treatment Business (2021-2026)
- 12.6.4 Biogen Cone-rod Dystrophy Treatment Product Portfolio
- 12.6.5 Biogen Recent Developments
- 12.7 Second Sight Medical
- 12.7.1 Second Sight Medical Company Information
- 12.7.2 Second Sight Medical Business Overview
- 12.7.3 Second Sight Medical Revenue in Cone-rod Dystrophy Treatment Business (2021-2026)
- 12.7.4 Second Sight Medical Cone-rod Dystrophy Treatment Product Portfolio
- 12.7.5 Second Sight Medical Recent Developments
- 12.8 GlaxoSmithKline
- 12.8.1 GlaxoSmithKline Company Information
- 12.8.2 GlaxoSmithKline Business Overview
- 12.8.3 GlaxoSmithKline Revenue in Cone-rod Dystrophy Treatment Business (2021-2026)
- 12.8.4 GlaxoSmithKline Cone-rod Dystrophy Treatment Product Portfolio
- 12.8.5 GlaxoSmithKline Recent Developments
- 12.9 Johnson And Johnson
- 12.9.1 Johnson And Johnson Company Information
- 12.9.2 Johnson And Johnson Business Overview
- 12.9.3 Johnson And Johnson Revenue in Cone-rod Dystrophy Treatment Business (2021-2026)
- 12.9.4 Johnson And Johnson Cone-rod Dystrophy Treatment Product Portfolio
- 12.9.5 Johnson And Johnson Recent Developments
- 12.10 Sanofi
- 12.10.1 Sanofi Company Information
- 12.10.2 Sanofi Business Overview
- 12.10.3 Sanofi Revenue in Cone-rod Dystrophy Treatment Business (2021-2026)
- 12.10.4 Sanofi Cone-rod Dystrophy Treatment Product Portfolio
- 12.10.5 Sanofi Recent Developments
- 12.11 Pfizer
- 12.11.1 Pfizer Company Information
- 12.11.2 Pfizer Business Overview
- 12.11.3 Pfizer Revenue in Cone-rod Dystrophy Treatment Business (2021-2026)
- 12.11.4 Pfizer Cone-rod Dystrophy Treatment Product Portfolio
- 12.11.5 Pfizer Recent Developments
- 12.12 Novartis
- 12.12.1 Novartis Company Information
- 12.12.2 Novartis Business Overview
- 12.12.3 Novartis Revenue in Cone-rod Dystrophy Treatment Business (2021-2026)
- 12.12.4 Novartis Cone-rod Dystrophy Treatment Product Portfolio
- 12.12.5 Novartis Recent Developments
- 12.13 Abbott Laboratories
- 12.13.1 Abbott Laboratories Company Information
- 12.13.2 Abbott Laboratories Business Overview
- 12.13.3 Abbott Laboratories Revenue in Cone-rod Dystrophy Treatment Business (2021-2026)
- 12.13.4 Abbott Laboratories Cone-rod Dystrophy Treatment Product Portfolio
- 12.13.5 Abbott Laboratories Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst